Clinical trials: Embryonal Neoplasm
Chronic Myelogenous Leukemia, Malignant Melanoma
A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies
This open label extension study will give an opportunity to the participants that have responded to the treatment with Pegylated-Interferon Alfa-2a (Pegasys) or Recombinant Interferon Alfa-2a (Roferon-A®) in prior clinical…
- Conditions
- Chronic Myelogenous Leukemia, Malignant Melanoma, Renal Cell Carcinoma
- Trial name
- NCT02829775
- Testing
- Pegylated Interferon Alfa-2a, Recombinant Interferon Alfa 2a
- Where
- 8 sites in Bulgaria, Canada and 5 more
- Volunteers
- 9 people
- Sponsor
- Hoffmann-La Roche
Melanoma
A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma
The purpose of this study was to evaluate safety and efficacy of the combination of an anti-PD-1 antibody (PDR001), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in patients with BRAF V600 mutant, unresectable…
- Trial name
- COMBI-i (NCT02967692)
- Testing
- Spartalizumab, Dabrafenib, Trametinib
- Where
- 179 sites in United States, Argentina and 27 more
- Volunteers
- 568 people
- Sponsor
- Novartis Pharmaceuticals
Recurrent Melanoma, Stage IV Melanoma
Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma
This phase I trial studies the side effects and best dose of ipilimumab when given together with whole brain radiation therapy or stereotactic radiosurgery in treating patients with melanoma with brain metastases.
- Conditions
- Recurrent Melanoma, Stage IV Melanoma, Tumors Metastatic to Brain
- Trial name
- NCT01703507
- Testing
- Ipilimumab, Whole-Brain Radiation Therapy (WBRT), Stereotactic Radiosurgery (SRS)
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Glioblastoma Multiforme, Brain Tumor
Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM
The high-grade malignant brain tumors, glioblastoma multiforme (GBM), comprise the majority of all primary brain tumors in adults.
- Trial name
- NCT01811498
- Testing
- Bevacizumab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Northwell Health
Glioblastoma, Astrocytoma, Grade IV
DC Migration Study for Newly-Diagnosed GBM
This randomized phase II study will assess the impact of pre-conditioning on migration and survival among newly diagnosed glioblastoma (GBM) patients who have undergone definitive resection and completed standard temozolomide…
- Conditions
- Glioblastoma, Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme
- Trial name
- ELEVATE (NCT02366728)
- Testing
- Unpulsed DCs, Td, Human CMV pp65-LAMP mRNA-pulsed autologous DCs
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Hypothalamic Obesity
Effects of Exenatide on Hypothalamic Obesity
The primary aim of this study is to evaluate the effect of Exenatide on weight status (change in body mass index) of children treated for craniopharyngioma that have developed hypothalamic obesity at Children's Hospitals and…
- Trial name
- NCT01061775
- Testing
- Exenatide
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Children's Hospitals and Clinics of Minnesota
Glioblastoma, Gliosarcoma
A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification
This study seeks to determine whether the addition of ABT-414 to concomitant radiotherapy and temozolomide (TMZ) followed by combination of ABT-414 with adjuvant TMZ prolongs overall survival (OS) among participants with newly…
- Trial name
- Intellance1 (NCT02573324)
- Testing
- Temozolomide, Depatuxizumab mafodotin, Radiation
- Where
- 212 sites in United States, Argentina and 26 more
- Volunteers
- 691 people
- Sponsor
- AbbVie
Glioblastoma Multiforme, Anaplastic Astrocytoma
Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
This study will offer a safe treatment for patients with relapsing recurring glioblastoma (GBM) or anaplastic astrocytoma (AA). The trial will test the hypothesis that Erlotinib (Tarceva, OSI-774) can be safely used up to a dose…
- Trial name
- NCT00301418
- Testing
- Erlotinib
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Melanoma
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma
The purpose of this study is to determine the safety, tolerability and dose limiting toxicities (DLTs) of VELCADE when administered in combination with interferon-alpha-2b (IFN-α-2b) to patients with metastatic malignant melanoma.
- Trial name
- NCT01462773
- Testing
- Bortezomib, Interferon Alfa-2b
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Melanoma
Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma
The purpose of the study is to determine whether additional doses of ipilimumab have a positive effect on survival in the treatment of advanced melanoma that has progressed after successful initial treatment with ipilimumab.
- Trial name
- NCT01709162
- Testing
- Ipilimumab, Chemotherapy
- Where
- 17 sites in United States, Austria and 3 more
- Volunteers
- 31 people
- Sponsor
- Bristol-Myers Squibb
Unresectable or Metastatic Melanoma
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
The purpose of the study is to estimate the response rate and compare overall survival of patients taking BMS-936558 to those taking study physician's choice of either Dacarbazine or Carboplatin and Paclitaxel
- Trial name
- NCT01721746
- Testing
- BMS-936558, Dacarbazine, Carboplatin
- Where
- 95 sites in United States, Austria and 12 more
- Volunteers
- 405 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumor
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
This research study is studying an investigational combination of drugs as a possible treatment for advanced solid tumors: melanoma, ovarian, renal, or colorectal cancer. The drugs involved in this study are: Pembrolizumab AMG386
- Trial name
- NCT03239145
- Testing
- Pembrolizumab, Trebananib
- Where
- 2 sites in United States
- Volunteers
- 62 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Malignancies
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01949 when given in combination with immune therapies in participants with advanced or metastatic malignancies.
- Trial name
- NCT03241173
- Testing
- INCAGN01949, Nivolumab, Ipilimumab
- Where
- 15 sites in United States
- Volunteers
- 52 people
- Sponsor
- Incyte Biosciences International Sàrl
Brain Metastases
An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis
This is a multicenter, randomized open-label Phase 2 study to assess the safety, efficacy and pharmacokinetic (PK) of 2 dosing regimens of encorafenib + binimetinib combination in patients with BRAFV600-mutant melanoma with brain…
- Trial name
- POLARIS (NCT03911869)
- Testing
- encorafenib, binimetinib
- Where
- 25 sites in United States, Argentina and 3 more
- Volunteers
- 13 people
- Sponsor
- Pfizer
Metastatic Melanoma, Locally Advanced Refractory/Recurrent Melanoma
Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors
To determine whether special tumor fighting cells that is taken from participants' tumors and grown in the laboratory and then given back to the participant will fight the participant's cancer when their immune system is…
- Conditions
- Metastatic Melanoma, Locally Advanced Refractory/Recurrent Melanoma, Metastatic Head and Neck Cancer, Locally Advanced Refractory/Recurrent Head and Neck Cancer
- Trial name
- NCT03991741
- Testing
- Autologous Tumor Infiltrating Lymphocytes, High-Dose Interleukin 2
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Gregory Daniels
Neuroblastoma, Sarcoma
Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
The purpose of this study is to find out what effects, good and/or bad treatment with a new combination of drugs, cyclophosphamide, topotecan, and bevacizumab has on the patient and their cancer.
- Trial name
- NCT01492673
- Testing
- Cyclophosphamide, Topotecan, and Bevacizumab
- Where
- 7 sites in United States, Canada
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanoma
Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma
Temozolomide (also known as TMZ) is a chemotherapy drug given by mouth. It is similar to DTIC, the only FDA-approved chemotherapy for melanoma, but because temozolomide is given by mouth, it can be given daily over a long period…
- Trial name
- NCT00591370
- Testing
- Temozolomide (TMZ)
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain Tumors, Spinal Cord Tumors
Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma
The goal of this clinical research study is to learn if lapatinib when given in combination with temozolomide can help to control ependymoma that has come back after treatment. The safety of this combination will also be studied.
- Trial name
- NCT00826241
- Testing
- Temozolomide, Lapatinib
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Melanoma, Melanoma Stage III
Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence
The main purpose of this study is to compare the efficacy of bempegaldesleukin plus nivolumab versus nivolumab in patients with completely resected Stage IIIA/B/C/D, or Stage IV cutaneous melanoma who are at high risk for…
- Conditions
- Melanoma, Melanoma Stage III, Melanoma Stage IV, Melanoma (Skin)
- Trial name
- PIVOT-12 (NCT04410445)
- Testing
- Bempegaldesleukin, Nivolumab
- Where
- 212 sites in United States, Australia and 15 more
- Volunteers
- 765 people
- Sponsor
- Nektar Therapeutics
Liver Neoplasms
Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors
This study is an open label prospective trial of TheraSphere treatment for patients who have liver metastases who have failed or are intolerant to other systemic or liver directed therapies.
- Trial name
- NCT01177007
- Testing
- TheraSphere, Yttrium-90 glass Microspheres
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Yale University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.